Oncotarget

Research Papers:

Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations

Yihan Ma, Peiqi Xu, Yanjun Mi, Wenyi Wang, Xiaoyan Pan, Xiaoting Wu, Qi He, Hongming Liu, Weiwei Tang and Hanxiang An _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:54965-54972. https://doi.org/10.18632/oncotarget.10829

Metrics: PDF 1586 views  |   HTML 1808 views  |   ?  


Abstract

Yihan Ma1, Peiqi Xu2, Yanjun Mi1, Wenyi Wang1, Xiaoyan Pan1, Xiaoting Wu1, Qi He1, Hongming Liu1, Weiwei Tang1, Hanxiang An1

1Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003, Fujian, China

2Reproduction Center, The Second Affiliated Hospital of Kunming Medical University 650101, Yunnan, China

Correspondence to:

Hanxiang An, email: anhanxiang@xmu.edu.cn

Keywords: circulating miRNA, microarray, NSCLC, EGFR, response

Received: April 29, 2016     Accepted: July 10, 2016     Published: July 24, 2016

ABSTRACT

Based on recognition of driver mutations, treatment paradigm for non-small-cell lung cancer (NSCLC) patients has been shifted. However, recently exon 19 deletion mutation (del19) of epidermal growth factor receptor (EGFR) clearly shows better clinical benefit over single-point substitution mutation L858R in exon 21 (L858R). The aim of this study was to investigate the difference by analyzing the expression of plasma microRNAs (miRNAs) of NSCLC patients with EGFR mutation del19 or L858R. MiRNA microarray of plasma from patients’ blood identified 79 mapped, network-eligible miRNAs (fold > 5), of which 76 were up regulated and 3 were down regulated. Genetic network was performed with Ingenuity Pathway Analysis (IPA). Among analysis, MYC, Argonaute2 (AGO2), Y-box binding protein 1 (YBX1), cyclin E1 (CCNE1) were involved in organismal abnormalities and cancer. Our findings provide information on the epigenetic signature of the two major sensitive mutations among NSCLC and add to the understanding of mechanisms underlying the different outcomes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10829